127 related articles for article (PubMed ID: 18561884)
1. Relative added value: what are the tools to evaluate it?
Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
[TBL] [Abstract][Full Text] [Related]
2. Relative Added Value: What are the Tools to Evalue it?
Jeunne CL; Woronoff-Lemsi MC; David N; Sahb Rd;
Therapie; 2008; 63(2):113-7. PubMed ID: 27393729
[TBL] [Abstract][Full Text] [Related]
3. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
4. Value of post-registration studies for reimbursement renewal.
Molimard M; Bamberger M; Vray M
Therapie; 2009; 64(3):203-13. PubMed ID: 19671433
[TBL] [Abstract][Full Text] [Related]
5. [Quantification of pharmacological progress by the French National Health Authorities].
Bouvenot G
Bull Acad Natl Med; 2006; 190(4-5):893-903; discussion 903-4. PubMed ID: 17195614
[TBL] [Abstract][Full Text] [Related]
6. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. [Drug evaluation by the French National Health Authority for reimbursement decisions].
Bouvenot G
Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
Avouac B
Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
[TBL] [Abstract][Full Text] [Related]
10. [The benefit provided by new medicinal products in 2005-2006--the viewpoint of the French National Authority for Health].
Bouvenot G
Therapie; 2007; 62(5):387-91. PubMed ID: 18206101
[TBL] [Abstract][Full Text] [Related]
11. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France.
Le Pen C; Priol G; Lilliu H
Eur J Health Econ; 2003; 4(1):30-6. PubMed ID: 15609166
[TBL] [Abstract][Full Text] [Related]
12. [Most innovative drugs labelled during the last years in paediatrics: does the paediatrician have the tools for their identification?].
Autret-Leca E
Arch Pediatr; 2010 Aug; 17(8):1237-42. PubMed ID: 20615673
[TBL] [Abstract][Full Text] [Related]
13. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
[TBL] [Abstract][Full Text] [Related]
14. Real medical benefit assessed by indirect comparison.
Falissard B; Zylberman M; Cucherat M; Izard V; Meyer F
Therapie; 2009; 64(3):225-32. PubMed ID: 19671436
[TBL] [Abstract][Full Text] [Related]
15. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of actual benefits of new drugs by the Transparency Committee].
Le Jeunne C
J Fr Ophtalmol; 2008 Jan; 31(1):90-3. PubMed ID: 18401307
[TBL] [Abstract][Full Text] [Related]
17. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
18. [The place of a new drug in the therapeutic strategy].
Castaigne A; Goehrs JM; Ravoire S
Therapie; 1999; 54(4):463-70. PubMed ID: 10667112
[TBL] [Abstract][Full Text] [Related]
19. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
Mussen F; Salek S; Walker S
Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of drug efficacy].
Massol J; Le Jeunne C
Presse Med; 2007 Mar; 36(3 Pt 2):505-11. PubMed ID: 17270386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
